Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.76% |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | -13.67% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 8.08% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.82% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.30% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -4.09% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 4.48% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 33.24% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 607.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.48% |
| Dec 31, 2025 | 8.72% |
| Sep 30, 2025 | 21.63% |
| Jun 30, 2025 | 14.48% |
| Mar 31, 2025 | 15.54% |
| Dec 31, 2024 | 16.67% |
| Sep 30, 2024 | 16.28% |
| Jun 30, 2024 | 22.10% |
| Mar 31, 2024 | 19.90% |
| Dec 31, 2023 | 20.82% |
| Sep 30, 2023 | 12.97% |
| Jun 30, 2023 | -1.80% |
| Mar 31, 2023 | -1.72% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 19.18% |
| Jun 30, 2022 | 33.60% |
| Mar 31, 2022 | 41.06% |
| Dec 31, 2021 | 31.39% |
| Sep 30, 2021 | 18.84% |
| Jun 30, 2021 | 12.11% |